Shots: The P-III IMbrave150 study involves assessing Tecentriq (IV, 1200mg) + Avastin (IV, 15mg/kg) vs Sorafenib (400mg, bid) in 501 (194 from China) patients in a ratio (2:1) in patients […]readmore
Tags : Chinese Patients
Shots: The P-II (NCT03209973) study result involves assessing of tislelizumab (200mg, IV, q3w) as a monothx. in 70 patients with R/R to autologous stem cell transplantation (ASCT) or 2L+ r/r […]readmore